CD4 and cancer: The emergence of this pan-cancer blueprint for predicting the response of different naive CD4+T cell phenotypes to immune checkpoint therapy can aid researchers in understanding the pathways by which various resistance mechanisms emerge after treatment, which is a significant step forward in the development of new cancer drugs and mechanistic research.